

### REMARKS

The present amendment is submitted to reduce the issues on appeal. Claims 1-3 and 13-17 are cancelled, claims 4 and 5 are rewritten in independent form, and claims 18-21 are amended to correct their dependency. A Version With Markings Showing Changes Made is attached. As these changes do not involve any introduction of new matter and do not raise any new issues on appeal, but rather reduce the issues on appeal by reducing the number of claims, entry is believed to be in order and is respectfully requested.

Respectfully submitted,



Holly D. Kozlowski  
Registration No. 30,468  
Dinsmore & Shohl LLP  
1900 Chemed Center  
255 East Fifth Street  
Cincinnati, Ohio 45202  
(513) 977-8568



**Version With Markings Showing Changes Made**

Claims 4, 5 and 18-21 are amended as follows:

4. (Twice Amended) [The composition according to claim 1,] A composition for the treatment of glaucoma and ocular hypertension comprising a therapeutically active and physiologically acceptable amount of a prostaglandin analogue which is a selective agonist for EP<sub>1</sub> prostanoid receptors, or a pharmaceutically acceptable salt or ester thereof, wherein the prostaglandin analogue is 15(R,S)-16,16-trimethylene-PGE<sub>2</sub> or an alkyl ester thereof.

5. (Twice Amended) [The composition according to claim 1,] A composition for the treatment of glaucoma and ocular hypertension comprising a therapeutically active and physiologically acceptable amount of a prostaglandin analogue which is a selective agonist for EP<sub>1</sub> prostanoid receptors, or a pharmaceutically acceptable salt or ester thereof, wherein the prostaglandin analogue is 13,14-dihydro-17-(3-fluorophenyl)-18,19,20-trinor-PGE<sub>2</sub> or an alkyl ester thereof.

18. (Amended) The method according to claim [6] 8, wherein R is C<sub>1-10</sub> alkyl, C<sub>3-8</sub> cycloalkyl or aryl-C<sub>2-5</sub> alkyl.

19. (Amended) The method according to claim [6] 8, wherein R1 is C<sub>3-7</sub> cycloalkyl or C<sub>3-7</sub> cycloalkenyl.

20. (Amended) The method according to claim [6] 8, wherein R2 is hydrogen, hydroxy, methyl, ethyl, methoxy or OCOR<sub>4</sub>, wherein R4 is C<sub>1-10</sub> alkyl or C<sub>3-8</sub> cycloalkyl.

21. (Amended) The method according to claim [6] 8, wherein R3 is a straight or branched chain saturated or unsaturated alkyl group having 3-8 carbon atoms, optionally interrupted by one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, each carbon atom optionally substituted with a substituent selected from C<sub>1-5</sub> alky, hydroxy and carbonyl groups, wherein the hydroxy and carbonyl are attached to carbon 15 of the prostaglandin structure, and said alkyl group optionally containing a C<sub>3-8</sub> cycloalkyl, optionally mono- or independently tri-substituted with C<sub>1-3</sub> alkyl, C<sub>1-3</sub> alkoxy, hydroxy, nitro, trifluoromethyl or halogen.

749159